Profil bibliographique

Karilyn Larkin

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

161Publications signalées

1816Citations signalées

2Affiliations récentes

Institutions déclarées

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University

Domaines associés

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia researchRenal Transplantation Outcomes and TreatmentsChronic Myeloid Leukemia Treatments

Publications récentes

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 articleOpenAlex

Phase II Study of Posttransplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis After HLA ‐Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

Brian C. Shaffer, Monzr M. Al Malki, Antonio Martin Jimenez Jimenez, Joseph Stanek et autres

0 citationsAmerican Journal of Hematology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.